TABLE 4.
In vitro and in vivo studies on the impact of nanoparticles on histone modification.
| Nanoparticles | Experiment model | Epigenetic effects | References |
|---|---|---|---|
| ZnO-NPs | Human bladder cancer T24 cells | Decrease of global histone 3 lysine 27 trimethylation (H3K27me3) at the RUNX3 gene promoter | Zhang et al. (2020) |
| CuO-NPs | Human A549 cells | Decrease of total HDAC activity | Kalaiarasi et al. (2017) |
| Reduction in the levels of HDAC1, HDAC2, HDAC3, HDAC5, HDAC9, and HDAC11 mRNA transcripts | |||
| Ag-NPs | Human A549, MCF7, and HaCat cells | Increase in histone 3 serine 10 phosphorylation (H3S10ph | Zhao et al. (2017) |
| As2O3-NPs | Human embryonic kidney (HEK) 293T | Decrease in global H4K16ac | Liu et al. (2015) |
| Au-NPs | Small airway epithelial cells | Decrease in H3K27me3 | Shyamasundar et al. (2015) |
| TiO2-NPs | Human adipose delivered stem cells (hASCs) | Increase of H3K4 methylation at the promoter region of osteogenic genes RUNX2 and osteocalcin (OC) | Lv et al. (2015) |
| Inhibition of histone demethylate | |||
| RBP2 expression | |||
| SiO2-NPs | Human A549 cells | Decreased levels of SIRT6 histone deacetylase (HDAC) transcript and protein | Zhang et al. (2018) |